STEPHANIE SMITH: Open Payments
NPI 1720563596 · TUPELO, MS. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,289 in 116 payments from 17 companies in 2025. Trend: 2023 $1,508 · 2024 $1,514 · 2025 $2,289
Food & beverage: $2,289
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 17 | $251 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 14 | $229 |
| GENZYME CORPORATION | 11 | $226 |
| Ardelyx, Inc. | 12 | $215 |
| Aimmune Therapeutics, Inc. | 11 | $209 |
| Phathom Pharmaceuticals, Inc. | 6 | $195 |
| Gilead Sciences, Inc. | 8 | $188 |
| Madrigal Pharmaceuticals | 6 | $183 |
| Takeda Pharmaceuticals U.S.A., Inc. | 8 | $145 |
| QOL Medical, LLC | 5 | $117 |
Products named: DUPIXENT, XIFAXAN, IBSRELA, ZENPEP, VOQUEZNA, REZDIFFRA, Sucraid, ENTYVIO.
Industry payments across MS — which companies pay providers there.
